Analyst Ratings January 28, 2026

Cantor Fitzgerald Lifts Texas Instruments Price Target to $225, Keeps Neutral Rating

Firm cites unexpectedly strong quarterly trends and management guidance as reasons for the higher valuation, while analysts offer varied outlooks

By Caleb Monroe TXN
Cantor Fitzgerald Lifts Texas Instruments Price Target to $225, Keeps Neutral Rating
TXN

Cantor Fitzgerald increased its price target on Texas Instruments to $225 from $190 and retained a Neutral rating after results the firm described as "surprisingly positive." The research house pointed to first-quarter sequential growth guidance not seen since 2010, improving gross margin trends and management expectations of order and backlog expansion. Other brokerages have also adjusted targets, producing a wide range of analyst views on the semiconductor company's near-term prospects.

Key Points

  • Cantor Fitzgerald raised its price target on Texas Instruments to $225 from $190 and kept a Neutral rating.
  • The upgrade follows "surprisingly positive" quarterly results, the first guided sequential growth in Q1 since 2010, and improving gross margin trends amid a 57% trailing-twelve-month gross profit margin.
  • Other analysts have moved price targets across a wide range, reflecting differing views on revenue and backlog momentum; Benchmark, Baird, UBS and Mizuho all revised targets after the quarter.

Cantor Fitzgerald raised its price target on Texas Instruments (NASDAQ:TXN) to $225.00 from $190.00 on Wednesday, while keeping a Neutral rating on the stock. The updated target implies upside relative to a reference share price of $196.63, although InvestingPro data notes the shares are trading at a price-to-earnings ratio of 35.95, signaling a premium valuation.

The firm highlighted what it called "surprisingly positive" quarterly results, including the company's first guided sequential growth for the first quarter since 2010. Cantor Fitzgerald pointed to stronger-than-expected gross margin trends as an additional supporting factor, following a recent trailing-twelve-month gross profit margin of 57%.

Management commentary underpins Cantor Fitzgerald’s view that a recovery is underway, driven by expanding orders and a growing backlog. The research note singled out strength in the data center market and a broadly based industrial recovery as notable contributors to the company's performance.

InvestingPro classifies Texas Instruments as a significant Semiconductors industry participant and reports 13.05% revenue growth over the past twelve months. Analysts tracked by InvestingPro anticipate that momentum to carry into fiscal 2026, with a forecast of 13% revenue growth for that year.

Cantor Fitzgerald’s valuation framework assumes Texas Instruments can generate roughly $9-10 of free cash flow per share in calendar year 2027, and the firm applies a 25x multiple to that expectation to support the raised price target. Management also signaled that pricing could decline in the low single digits percentage in 2026.

The company’s financial position was described as strong, reflected in a "GOOD" overall financial health score and a current ratio of 4.35, indicating comfortable near-term liquidity.

Texas Instruments is scheduled to present its Capital Management Presentation on February 24. Cantor Fitzgerald expects that event to sharpen investor focus on the company’s free cash flow potential.

Investors may also note the company’s long-running dividend record. InvestingPro data shows Texas Instruments has raised dividends for 22 consecutive years and maintained dividend payments for 56 years.


Recent quarter and analyst reactions

In its fourth-quarter 2025 results, Texas Instruments recorded an earnings per share of $1.27, slightly missing the $1.29 analysts had forecast. Revenue for the quarter came in at $4.42 billion, short of the $4.45 billion consensus estimate.

Following the results and accompanying outlook, several brokerages adjusted their price targets for the stock. Benchmark increased its target to $250, citing strong guidance for the upcoming quarter. Baird lifted its target to $225, calling the company’s first-quarter outlook a positive surprise. UBS raised its target to $260, pointing to improving revenue trends and constructive commentary on bookings and backlog. Mizuho raised its target to $160 but retained an Underperform rating, noting December quarter revenue of $4.4 billion that it characterized as in line with consensus.

These differing revisions reflect a broad spectrum of analyst expectations about the company’s near-term performance and the durability of improving revenue and margin trends.


What this means for market participants

Cantor Fitzgerald’s higher price target rests on a combination of better-than-expected recent results, stronger margins, management guidance suggesting sequential growth, and the firm’s projection of robust free cash flow by 2027. At the same time, the stock’s elevated P/E multiple and mixed analyst reactions underscore that market participants remain divided on how to price the company amid evolving demand dynamics across data center and industrial end markets.

Investors will likely watch the February 24 Capital Management Presentation closely for further clarity on cash generation and capital allocation plans.

Risks

  • Stock trades at a high P/E of 35.95, indicating a premium valuation and potential valuation sensitivity - this could affect investors in the Semiconductors and broader Technology sectors.
  • Fourth-quarter 2025 results slightly missed consensus on both EPS ($1.27 versus $1.29) and revenue ($4.42 billion versus $4.45 billion), introducing near-term execution risk for earnings-focused investors.
  • Analyst expectations vary widely, as evidenced by divergent price target moves from Benchmark, Baird, UBS and Mizuho, creating uncertainty about consensus views on demand and margin sustainability in data center and industrial markets.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026